<DOC>
	<DOCNO>NCT02852486</DOCNO>
	<brief_summary>The purpose study evaluate treatment-free remission imatinib discontinuation patient chronic myeloid leukemia deep molecular response . Before discontinuation , patient receive pioglitazone associate imatinib 3 month .</brief_summary>
	<brief_title>Study Imatinib Discontinuation Chronic Myeloid Leukemia With Deep Molecular Response</brief_title>
	<detailed_description>Treatment chronic myeloid leucemia ( CML ) tyrosine kinase inhibitor ( TKIs ) change dramatically prognosis CML , high rate cytogenetic molecular remission increase overall progression-free survival . However , long-term treatment CML high cost health system , due price drug need continue use . In addition , chronic adverse effect may compromise quality life patient . Discontinuation trial TKIs develop order identify group patient may benefit treatment discontinuation obtain deeper molecular responses.The primary objective study evaluate treatment free remission ( TFR ) imatinib discontinuation patient treat 3 year imatinib deep molecular response stable two year ( define present study molecular response 4.5 log reduction breakpoint cluster region ( BCR ) -Abelson murine leukemia viral oncogene homolog 1 ( ABL ) transcript level accord international scale ( MR 4.5 ; BCR-ABL/ABL ratio &lt; = 0.0032 % ) . Patients criteria receive pioglitazone 3 month concomitant imatinib , prior discontinuation . After imatinib discontinuation , patient evaluate molecular assessment BCR-ABL transcript level quantitative real time polymerase chain reaction ( RQ-PCR ) monthly first year , every 2 month second year every 3 month . The criterion restart treatment loss major molecular response ( MMR ) , document single RQ-PCR test &gt; 0.1 % , confirm loss 4 log reduction molecular response ( MR4.0 ) , 2 consecutive RQ-PCR test &gt; 0.01 % .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>CML chronic phase treatment imatinib 3 year MR4.5 ( RQPCR &lt; ou =0.0032 % ) confirm 4 RQPCR test BCRABL last 2 year ( 2 test within last 6 month ) Eastern Cooperative Oncology Group Performance Status ( ECOG ) 02 Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 reference level Bilirubins ≤ 1.5 reference level Contraceptive precaution woman Patients less 18 year Severe organ disfunction ( liver kidney ) Severe cardiovascular disease : grade IIV New York Heart Association ( NYHA ) acute myocardial infarction last six month , symptomatic arrhythmia Fluid retention grade 3 4 Osteoporosis treatment Patients previous CML accelerate blast phase blast Philadelphia positive ( Ph+ ) acute lymphoid leukemia ( ALL ) BCRABL mutation relate resistance Previous allogeneic bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>BCR-ABL Positive</keyword>
	<keyword>Leukemia , Chronic Myeloid</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Pioglitazone</keyword>
</DOC>